Condition
Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8
Total Trials
5
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
5Total
Not Applicable (4)
P 3 (1)
Trial Status
Recruiting1
Terminated1
Not Yet Recruiting1
Active Not Recruiting1
Withdrawn1
Clinical Trials (5)
Showing 5 of 5 trials
NCT07468903Not ApplicableNot Yet Recruiting
Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer
NCT04624256Not ApplicableActive Not Recruiting
Germline DNA-Based Radiosensitivity Biomarker Influence on Toxicity Following Prostate Radiotherapy, GARUDA Trial
NCT06500169Not ApplicableRecruiting
Golf Recreational Exercise for Enhanced Survivorship in Prostate Cancer Survivors
NCT04457245Phase 3TerminatedPrimary
Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer
NCT04399824Not ApplicableWithdrawn
Focal Radiation Therapy for the Treatment of Low or Intermediate-Risk Prostate Cancer
Showing all 5 trials